Total Payments
$64,022
2024 Payments
$13,968
Companies
12
Transactions
47
Medicare Patients
1,167
Medicare Billing
$243,976
Payment Breakdown by Category
Consulting$37,125 (58.0%)
Other$21,132 (33.0%)
Travel$2,603 (4.1%)
Research$2,097 (3.3%)
Food & Beverage$1,046 (1.6%)
Education$18.09 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $37,125 | 20 | 58.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $8,378 | 3 | 13.1% |
| Honoraria | $7,380 | 3 | 11.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,375 | 2 | 8.4% |
| Travel and Lodging | $2,603 | 8 | 4.1% |
| Unspecified | $2,097 | 2 | 3.3% |
| Food and Beverage | $1,046 | 8 | 1.6% |
| Education | $18.09 | 1 | 0.0% |
Payments by Type
General
$61,925
45 transactions
Research
$2,097
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $19,425 | 7 | $0 (2023) |
| SpringWorks Therapeutics, Inc. | $10,501 | 6 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $10,386 | 8 | $0 (2017) |
| Deciphera Pharmaceuticals Inc. | $6,749 | 8 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $6,165 | 5 | $0 (2021) |
| Daiichi Sankyo Inc. | $3,083 | 1 | $0 (2020) |
| Aadi Bioscience, Inc. | $2,550 | 2 | $0 (2023) |
| Eli Lilly and Company | $2,097 | 2 | $0 (2018) |
| Merck Sharp & Dohme LLC | $1,611 | 2 | $0 (2024) |
| Foundation Medicine, Inc. | $1,203 | 4 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,968 | 14 | SpringWorks Therapeutics, Inc. ($10,501) |
| 2023 | $3,375 | 3 | Aadi Bioscience, Inc. ($2,550) |
| 2022 | $1,593 | 1 | Merck Sharp & Dohme LLC ($1,593) |
| 2021 | $5,210 | 4 | AstraZeneca Pharmaceuticals LP ($4,110) |
| 2020 | $8,788 | 5 | Deciphera Pharmaceuticals Inc. ($3,300) |
| 2019 | $253.97 | 2 | Advanced Bionics, LLC ($233.92) |
| 2018 | $19,500 | 7 | Bayer HealthCare Pharmaceuticals Inc. ($17,500) |
| 2017 | $11,336 | 11 | Novartis Pharmaceuticals Corporation ($10,386) |
All Payment Transactions
47 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2024 | SpringWorks Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,850.00 | General |
| 09/25/2024 | SpringWorks Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $131.32 | General |
| 09/25/2024 | SpringWorks Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $15.62 | General |
| 09/21/2024 | Deciphera Pharmaceuticals Inc. | VIMSELTINIB (Drug) | Honoraria | Cash or cash equivalent | $1,665.00 | General |
| Category: ONCOLOGY | ||||||
| 09/21/2024 | Deciphera Pharmaceuticals Inc. | VIMSELTINIB (Drug) | Travel and Lodging | In-kind items and services | $375.00 | General |
| Category: ONCOLOGY | ||||||
| 09/21/2024 | Deciphera Pharmaceuticals Inc. | VIMSELTINIB (Drug) | Travel and Lodging | In-kind items and services | $131.60 | General |
| Category: ONCOLOGY | ||||||
| 09/21/2024 | Deciphera Pharmaceuticals Inc. | VIMSELTINIB (Drug) | Food and Beverage | In-kind items and services | $89.00 | General |
| Category: ONCOLOGY | ||||||
| 09/21/2024 | Deciphera Pharmaceuticals Inc. | VIMSELTINIB (Drug) | Food and Beverage | In-kind items and services | $78.00 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2024 | SpringWorks Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $78.99 | General |
| 07/24/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Consulting Fee | Cash or cash equivalent | $4,900.00 | General |
| Category: DESMOID TUMORS | ||||||
| 06/07/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2024 | SpringWorks Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,525.00 | General |
| 09/28/2023 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| Category: Oncology | ||||||
| 06/02/2023 | Aadi Bioscience, Inc. | Fyarro (Drug) | Honoraria | Cash or cash equivalent | $2,415.00 | General |
| Category: Cancer | ||||||
| 06/02/2023 | Aadi Bioscience, Inc. | Fyarro (Drug) | Food and Beverage | In-kind items and services | $134.56 | General |
| Category: Cancer | ||||||
| 09/07/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,592.50 | General |
| 11/30/2021 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 07/06/2021 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| 06/14/2021 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,027.50 | General |
| 04/16/2021 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
| 12/24/2020 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Honoraria | Cash or cash equivalent | $3,300.00 | General |
| Category: ONCOLOGY | ||||||
| 12/21/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| 12/09/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF FIRST-LINE METASTATIC PANCREATIC CANCER | Eli Lilly and Company | $1,647 | 1 |
| A PHASE 1B OPEN-LABEL - PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING GEMCITABINE AND DOCETAXEL WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA | Eli Lilly and Company | $450.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 284 | 520 | $396,393 | $64,977 |
| 2022 | 6 | 261 | 478 | $360,896 | $62,435 |
| 2021 | 7 | 327 | 518 | $280,480 | $66,376 |
| 2020 | 8 | 295 | 457 | $240,329 | $50,188 |
Total Patients
1,167
Total Services
1,973
Medicare Billing
$243,976
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 111 | 301 | $207,389 | $33,696 | 16.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 45 | 80 | $78,320 | $12,529 | 16.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 36 | 36 | $43,632 | $7,361 | 16.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 42 | 42 | $36,918 | $6,438 | 17.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 50 | 61 | $30,134 | $4,954 | 16.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 100 | 286 | $197,054 | $32,993 | 16.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 43 | 65 | $63,635 | $11,174 | 17.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 40 | 40 | $48,480 | $8,044 | 16.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 33 | 33 | $29,007 | $6,210 | 21.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 26 | 31 | $15,314 | $2,467 | 16.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 19 | 23 | $7,406 | $1,547 | 20.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 104 | 241 | $114,475 | $28,324 | 24.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 44 | 69 | $44,229 | $11,579 | 26.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 43 | 43 | $39,517 | $8,796 | 22.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 39 | 39 | $34,281 | $7,491 | 21.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 64 | 92 | $35,236 | $7,455 | 21.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 20 | 21 | $6,762 | $1,447 | 21.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 13 | 13 | $5,980 | $1,285 | 21.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 76 | 164 | $77,900 | $15,999 | 20.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 49 | 49 | $43,071 | $9,351 | 21.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 35 | 35 | $32,165 | $7,053 | 21.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 31 | 50 | $32,050 | $6,884 | 21.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 53 | 89 | $34,087 | $6,261 | 18.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 28 | 46 | $14,812 | $3,237 | 21.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 11 | 12 | $3,648 | $870.28 | 23.9% |
About Dr. Tony Philip, MD
Dr. Tony Philip, MD is a Hematology & Oncology healthcare provider based in New Hyde Park, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/17/2008. The National Provider Identifier (NPI) number assigned to this provider is 1174772982.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tony Philip, MD has received a total of $64,022 in payments from pharmaceutical and medical device companies, with $13,968 received in 2024. These payments were reported across 47 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($37,125).
As a Medicare-enrolled provider, Philip has provided services to 1,167 Medicare beneficiaries, totaling 1,973 services with total Medicare billing of $243,976. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location New Hyde Park, NY
- Active Since 09/17/2008
- Last Updated 09/17/2008
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1174772982
Products in Payments
- Stivarga (Drug) $19,425
- VOTRIENT (Drug) $10,386
- OGSIVEO (Drug) $4,900
- QINLOCK (Drug) $4,410
- Enhertu (Drug) $3,083
- Fyarro (Drug) $2,550
- VIMSELTINIB (Drug) $2,339
- FOUNDATIONACT (Device) $853.03
- FOUNDATIONONE CDX (Device) $350.00
- HiResolution Bionic Ear System (Device) $233.92
- WELIREG (Drug) $18.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New Hyde Park
Richard Gralla, Md, MD
Hematology & Oncology — Payments: $351,325
Hematology & Oncology $351,325
Joanna Rhodes, Md, Msce, MD, MSCE
Hematology & Oncology — Payments: $130,301
Hematology & Oncology $130,301
Tarun Wasil, Md, MD
Hematology & Oncology — Payments: $124,553
Hematology & Oncology $124,553
Robert Weiner, M.d, M.D
Hematology & Oncology — Payments: $42,221
Hematology & Oncology $42,221
Dr. Richard Forte, M.d, M.D
Hematology & Oncology — Payments: $34,915
Hematology & Oncology $34,915
Xinhua Zhu
Hematology & Oncology — Payments: $16,919
Hematology & Oncology $16,919